EAM
EIGR

EverPoint Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

EverPoint Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-667
Closed -$5.86M – 614
2014
Q4 		$5.86M Buy
+667
New +$3.87M 0.13% 230

Other funds holding EIGR

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EverPoint Asset Management's EIGR Position: Q1 2015 in Review

EverPoint Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2015, closing a stake of 667 shares — an estimated $5.86M sold.

EverPoint Asset Management first reported a position in EIGR in Q4 2014 and held it in 1 quarter. The position peaked at $5.86M in Q4 2014. 84 funds tracked by Wall St. Rank hold EIGR as of Q1 2015.

  • EverPoint Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 667 Eiger BioPharmaceuticals, Inc. shares in Q1 2015, an estimated $5.86M.
  • EverPoint Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • EverPoint Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $5.86M in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2015.

Based on EverPoint Asset Management's 13F filing for Q1 2015, filed 15 May 2015.